Systematic review with network meta‐analysis: pharmacological prophylaxis against post‐ ERCP  pancreatitis by Akshintala, V. S. et al.
Systematic review with network meta-analysis:
pharmacological prophylaxis against post-ERCP pancreatitis
V. S. Akshintala*, S. M. Hutﬂess*, E. Colantuoni†, K. J. Kim*, M. A. Khashab*, T. Li‡, B. J. Elmunzer§, M. A. Puhan‡,
A. Sinha*, A. Kamal*, A. M. Lennon*, P. I. Okolo*, M. K. Palakurthy¶, A. N. Kalloo* & V. K. Singh*
*Division of Gastroenterology, Johns
Hopkins Medical Institutions,
Baltimore, MD, USA.
†Department of Biostatistics, Johns
Hopkins Bloomberg School of Public
Health, Baltimore, MD, USA.
‡Department of Epidemiology, Johns
Hopkins Bloomberg School of Public
Health, Baltimore, MD, USA.
§Division of Gastroenterology,
University of Michigan Medical
Center, Ann Arbor, MI, USA.
¶Department of Gastroenterology,
Andhra Medical College,
Visakhapatnam, India.
Correspondence to:
Dr V. K. Singh, Division of
Gastroenterology, Johns Hopkins
Hospital, 1830 East Monument Street,
Room 428, Baltimore, MD 21205,
USA.
E-mail: vsingh1@jhmi.edu
Publication data
Submitted 7 July 2013
First decision 3 August 2013
Resubmitted 18 September 2013
Accepted 29 September 2013
EV Pub Online 20 October 2013
As part of AP&T’s peer-review process, a
technical check of this meta-analysis was
performed by Mr M. Siddiqui.
SUMMARY
Background
The efﬁcacy of many pharmacological agents for preventing post-ERCP
pancreatitis (PEP) has been evaluated in randomised controlled trials
(RCTs), but it is unclear which agent(s) should be used in clinical practice.
Network meta-analyses of RCTs are used to simultaneously compare several
agents to determine their relative efﬁcacy and identify priority agents for
comparison in future RCTs.
Aim
To evaluate pharmacological agents for the prevention of PEP by conduct-
ing a network meta-analysis of RCTs.
Methods
We searched MEDLINE, EMBASE and Cochrane Library databases for
RCTs that evaluated the efﬁcacy of agents for preventing PEP. RCTs were
simultaneously analysed using random-effects network meta-analysis under
the Bayesian framework to identify the best agents. The efﬁcacy of agents
was ordered according to the probability of being ranked as any of the top
three best performing agents.
Results
The network meta-analysis included 99 RCTs evaluating 16 agents in 25 313
patients. Topical epinephrine (adrenaline) was the most efﬁcacious agent
with 85.9% probability of ranking among the top three agents, followed by
nafamostat (51.4%), antibiotics (44.5%) and NSAIDs (42.8%). However, in a
sensitivity analysis including only rectal NSAIDs, NSAIDs moved from
fourth rank to second (58.1%). Patients receiving topical epinephrine, com-
pared with placebo, had a 75% reduced risk of PEP (OR 0.25, 95% probabil-
ity interval 0.06–0.66).
Conclusions
Topical epinephrine and rectal NSAIDs are the most efﬁcacious agents for
preventing post-ERCP pancreatitis, based on existing RCTs. Combinations
of these agents, which act on different steps in the pathogenesis of post-
ERCP pancreatitis, should be evaluated in future trials.
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INTRODUCTION
Post-ERCP pancreatitis (PEP) is the most common com-
plication of endoscopic retrograde cholangiopancreatog-
raphy (ERCP), with an estimated incidence of 3–7%
among average-risk patients and 15–20% among patients
at high risk for developing PEP.1–4 There has been an
interest in the pharmacological prevention of PEP since
1977, when randomised controlled trials (RCTs) using
aprotinin5 and calcitonin6 were published.
Only one of three professional societies with guide-
lines has recommended a pharmacological agent for PEP
prophylaxis. The Japanese Guidelines (JPN)7 and Ameri-
can Society of Gastrointestinal Endoscopy8 have emphas-
ised the lack of efﬁcacy of certain pharmacological
agents to prevent PEP, but they have not advocated in
favour of any single pharmacological agent. However,
the 2010 guidelines of the European Society of Gastroin-
testinal Endoscopy9 recommended rectal NSAIDs for the
prevention of PEP based on ﬁve placebo-controlled
RCTs. A landmark multicentre RCT published in 2012
also demonstrated the superiority of rectal NSAIDs over
placebo in high-risk patients.10
While seven RCTs have demonstrated the efﬁcacy of
rectal NSAIDs, these were all compared with placebo
and it is unknown if rectal NSAIDs are better for the
prevention of PEP when compared with other pharma-
cological agents studied in RCTs. Given the lack of
head-to-head RCTs between the numerous pharmacolog-
ical agents studied for PEP prophylaxis, statistical tech-
niques, such as network meta-analyses (NMAs),11, 12 can
be used to perform direct and indirect comparisons of
agents evaluated in prior RCTs to determine which
agent(s) is(are) most efﬁcacious for preventing PEP. The
objective of this study was to conduct a NMA of RCTs
of pharmacological agents for preventing PEP among
patients undergoing ERCP.
MATERIALS AND METHODS
Literature Search
We searched PUBMED, EMBASE and Cochrane Central
Register of Controlled Trials using a combination of
MESH terms, EMTREE terms and keywords that
describe ERCP (Appendix S1). We used the Cochrane
Highly Sensitive Search Strategy and the RCT ﬁlter for
EMBASE as recommended by the Cochrane Handbook
6.4.11 to identify RCTs.13 The search had no language
restrictions and included the period since inception of
each database to June 2013. We also hand searched the
bibliographies of relevant systematic reviews14–31 and
scanned the titles of journals that publish high-impact
gastroenterology trials, including the New England Jour-
nal of Medicine, Annals of Internal Medicine, Gastroen-
terology, Gut, American Journal of Gastroenterology,
Gastrointestinal Endoscopy, Clinical Gastroenterology and
Hepatology, Endoscopy, Alimentary Pharmacology and
Therapeutics, Pancreas and Pancreatology journals, pub-
lished between January 2013 and June 2013 to identify
additional trials for inclusion.
Eligibility criteria
We included RCTs that enrolled patients undergoing
ERCP and that compared at least two agents, including
placebo, for preventing PEP. We excluded conference
abstracts, as the information required for the assessment
of study quality as well as details related to the agent
and outcome could not be adequately obtained. We also
excluded studies reporting the incidence of hyperamyla-
saemia without reporting on the clinical signs of PEP.
For studies published in languages other than English,
we recruited native speakers of the respective language
with a scientiﬁc background, to assist with determining
trial eligibility and data abstraction. Agents were required
to be evaluated in at least two eligible RCTs for inclusion
in the NMA.
Article review and data abstraction
We employed a systematic approach for reviewing the
search results in accordance with the Cochrane guide-
lines32 and Agency for Healthcare Research and Quality
Methods Guide.33 Two reviewers independently reviewed
titles, abstracts and full texts. In the title review stage,
any study having a title potentially related to ERCP was
included. In the abstract review stage, any study evaluat-
ing pharmacological agents in the setting of ERCP was
included. During the full-text review, RCTs that com-
pared at least two agents for the prophylaxis of PEP
were eligible for data abstraction. We included articles
that reported on the incidence of PEP, even if the num-
ber of events was zero. During the abstract and full-text
review stages, we resolved conﬂicts by consensus. We
consulted with an epidemiologist, biostatistician and/or
endoscopist when necessary during the review process.
One reviewer abstracted data that were veriﬁed by a
second reviewer, using pilot-tested data extraction sheets
containing all the variables of interest, including study
design, population and agent characteristics, as well as
the incidence, severity and mortality of PEP. We assessed
study quality in terms of random sequence generation,
allocation concealment, blinding of the patients and
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investigators, bias introduced by the investigators due to
placement of pancreatic duct stents, and a summary of
assessment of bias across the study using the Cochrane
Collaboration’s tool for assessing risk of bias in RCTs.34
Outcomes of interest
The incidence of PEP was the primary outcome of inter-
est. Secondary outcomes were the severity and mortality
of PEP.
Statistical analysis
We used a Bayesian random-effects model for network
meta-analysis (NMA) in WinBUGS statistical analysis
program version 1.4.3 (MRC Biostatistics Unit, Institute
of Public Health, Cambridge, UK) with an adjustment
provided for three-arm trials as described by Ades
et al.35 For RCTs that compared multiple doses of the
same agent in different arms, the results from different
arms were pooled for analysis. This pooling was carried
out to allow our model to attain equilibrium (see below).
We created a model for each outcome of interest: inci-
dence, severity and mortality of PEP.
To model the most efﬁcacious agent in the NMA, the
Bayesian algorithm utilised data from the RCTs with
non-informative priors and was simulated to run 160 000
draws of probable results. Each draw provided an esti-
mate of the incidence, severity or mortality rate for each
agent and this was used to determine the ranking of each
agent in relation to the other agents in the NMA. The
percentage of times each agent ranked among the top
three performing agents (maximum of 300%), among all
the draws, was used to identify the most efﬁcacious agent.
The initial 80 000 draws were excluded to avoid the
inﬂuence of the initially unstable values.36 We summar-
ised the ranking results using rankograms.37 We also cal-
culated pairwise odds ratios (OR) with 95% probability
intervals (PI)38 to compare the relative odds of incidence,
severity or mortality with placebo as the reference agent.
The direction of the point estimate (OR < 1 or OR > 1)
that provides the rank is accorded greater importance
than the absolute value of the OR or the 95% PI for our
interpretation of the results in this NMA. The attainment
of equilibrium of the model, i.e. a state in which the
model gives stable results after running multiple itera-
tions, was evaluated by examining the Markov chain
(MC) error for each outcome. The model was considered
to be stable if the MC error was less than 5% of the stan-
dard deviation (s.d.) of the corresponding rank or OR.
We evaluated heterogeneity and consistency within
the NMA by quantitative assessment using statistical
methods. Heterogeneity was quantiﬁed by including a
random intercept for study within the Bayesian NMA
model. The variance of the random intercept represents
the variation across studies in the agent–outcome rela-
tionship. Because high-risk status was thought to be the
most likely source of potential heterogeneity, an analysis
that excluded RCTs that only included patients at high
risk of developing PEP was conducted.
A Bayesian approach for a multivariate meta-regres-
sion model39 was used to assess consistency of the model
across different designs of comparison between the same
pairs of agents, i.e. agents A and B can be compared by
calculating OR from a trial comparing A vs. B vs. C or
A vs. B (Appendix S1). The consistency was treated as a
ﬁxed effect and represents the difference in expected out-
comes comparing the possible trial designs. A Wald test
with degrees of freedom equal to the number of consis-
tency ﬁxed effects was used.
Sensitivity analyses
Multiple separate analyses were conducted to evaluate
the certainty of results. The most efﬁcacious agent was
excluded from the analysis and the model was rerun to
assess the inﬂuence of the excluded agent on the ranking
order. The agents that were evaluated only among high-
risk patients were compared in a separate analysis to
determine if the rank order of the most efﬁcacious
agents was similar in this subgroup. To assess for the
inﬂuence of route of administration and dosage on the
efﬁcacy of these agents, the 16 agents were broken down
into 30 categories and a separate analysis was conducted.
Considering the clinical guidelines’ recommendation of
using rectal NSAIDs9 over other routes of NSAIDs,
RCTs evaluating oral and intramuscular route for NSA-
IDs were excluded to evaluate the efﬁcacy of rectal NSA-
IDs over other agents.
The number needed to treat (NNT) was calculated for
each of the 16 agents by using the OR between the agent
and placebo obtained from NMA based on the methods
described by Chatellier et al.40 The pooled incidence of
PEP among the placebo groups of all RCTs weighted by
the sample size of each RCT was calculated for this pur-
pose.
RESULTS
Search results and study characteristics
The electronic searches resulted in 9094 titles, of which
94 RCTs met the inclusion criteria for NMA. We
identiﬁed an additional ﬁve RCTs from hand searching,
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resulting in a total of 99 RCTs for this analysis (Fig-
ure 1). A total of 25 313 patients were randomly
assigned to one of 16 agents or placebo, among whom
13 285 (52.5%) were women. The mean age of the
patients in these RCTs ranged from 42 to 70 years.
Among the RCTs that met the inclusion criteria for
NMA, the ﬁrst RCT was published in 1984 and the most
recent publication was from 2012.
The 16 pharmacological agents that met the inclusion
criteria for the NMA included allopurinol, antibiotics
(cefotaxime, ceftazidime, ciproﬂoxacin, metronidazole or
oﬂoxacin), corticosteroids (prednisone, methyl predniso-
lone and hydrocortisone), epinephrine (adrenaline),
gabexate, glyceryl trinitrate, heparin, interleukin (IL)-10,
NSAIDs (indomethacin, diclofenac), N-acetylcysteine
(NAC), nafamostat, nifedipine, octreotide, secretin,
Records excluded due to title and
Full-text articles excluded (n = 140)
abstract not meeting the inclusion
criteria
13 duplicates
26 published as conference abstracts
52 not randomised control trial
44 evaluated drugs in ERCP setting but
did not report PEP incidence
2 compared different sub-types of
same drug
2 used a combination of multiple drugs
for PEP prophylaxis
1 compared a drug to endoscopic
intervention for PEP prophylaxis
Randomised controlled trials included in the Network Meta-Analysis
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9 trials were 3 arm trials
90 were 2 arm trials
6 trials evaluated Allopurinol
4 trials evaluated Antibiotics
6 trials evaluated Corticosteroids
2 trials evaluated Epinephrine
10 trials evaluated Gabexate
9 trials evaluated GTN
3 trials evaluated Heparin
3 trials evaluated IL - 10
2 trials evaluated N-Acetylcysteine
3 trials evaluated Nafamostat
3 trials evaluated Nifedipine
10 trials evaluated NSAIDS
22 trials evaluated Octreotide
18 trials evaluated Somatostatin
2 trials evaluated Secretin
8 trials evaluated Ulinastatin
Records identified through database searching
(n = 9094)
Records after duplicates removed
(n = 7050)
Records screened
Full-text articles assessed for eligibility
(n = 7050)
(n = 253)
Eligible randomised controlled trials
identified from hand search
Randomised controlled trials included in
the systematic review
(n = 4)
(n = 117)
(n = 99)
(n = 6756)
Figure 1 | Preferred reporting items for systematic reviews and meta-analyses (PRISMA) ﬂow diagram showing the
inclusion of studies from literature review through network meta-analysis.
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somatostatin and ulinastatin (Appendix S2, References).
There were another 20 agents that did not meet the
inclusion criteria for NMA because they were evaluated
in a single RCT. The 20 excluded trials are further
described in Appendix S2 (Table S1). None of the 20
agents showed statistically signiﬁcant efﬁcacy based on
the singe trial and are unlikely to have inﬂuenced the
results of NMA if included in the analysis.
The NMA included 12 head-to-head trials and 87 pla-
cebo-controlled trials. There were nine three-arm RCTs41–
49 that evaluated two different agents with placebo and
seven RCTs50–56 that evaluated single agents at different
dosages with placebo. There were 85 RCTs published in
English, 5 in Chinese,44, 45, 48, 57 2 in Italian,58, 59 2 in
Spanish,60, 61 2 in German,62, 63 1 in Hungarian,64 1 in
Korean46 and 1 in Japanese.65 On assessing the quality of
RCTs, there were 62 (62.6%) RCTs that had adequate ran-
dom sequence generation, 53 (53.5%) that had adequate
allocation concealment and 60 (60.6%) that had adequate
blinding of patients and study personnel (Appendix S2,
Figure S1). However, 19 (19.2%) had a high risk of bias
due to the placement of pancreatic duct stents in some of
their study patients. A total of 73 (73.7%) RCTs were con-
ducted at tertiary care or referral centres. Of the 47 RCTs
that reported on conﬂicts of interest, there were 14 (29.8%)
RCTs that reported receiving support from industry.
The deﬁnition of PEP was variable across studies
(Appendix S2, Table S2), but 74 (74.7%) of the 99 RCTs
deﬁned PEP using a consensus deﬁnition as ‘clinical pan-
creatitis with serum amylase at least three times normal
at more than 24 hours after the procedure, requiring
hospital admission or a prolongation of planned admis-
sion’.66 Twenty-four (24.2%) studies reported using deﬁ-
nitions similar to the consensus deﬁnition for PEP.
Amylase and lipase were used to deﬁne PEP in 15
(15.2%) studies, while two (2%) studies used the results
of abdominal imaging in addition to elevations in pan-
creatic enzymes. The results of abdominal imaging con-
sistent with PEP, without regard to enzyme levels, were
used by one study to deﬁne PEP.
Efﬁcacy of pharmacological agents to prevent PEP
Figure 2 displays a network ﬁgure of all the agents
included in this NMA and the number of RCTs compar-
ing different agents. Figure 3 provides a graphical repre-
sentation of the ranking order, which reﬂects efﬁcacy.
Among the 16 agents, topical epinephrine was the most
efﬁcacious agent to prevent PEP, with an 86.5% probabil-
ity of being ranked in the top three positions followed by
nafamostat (52%), antibiotics (45.4%), NSAIDs (40.9%),
secretin (26.6%) and somatostatin (20.5%). The corre-
sponding ORs for these six agents compared with
placebo were 0.25 (95% PI 0.06–0.64), 0.41 (95% PI
0.17–0.86), 0.46 (95% PI 0.15–1.06), 0.42 (95% PI 0.26–
0.64), 0.62 (95% PI 0.18–1.60) and 0.47 (95% PI 0.30–
0.69) respectively. The OR comparing the top two agents,
topical epinephrine and nafamostat, with each other was
0.42 (95% PI 0.13–2.18) (Appendix S2, Table S3).
Efﬁcacy of pharmacological agents to prevent severe
PEP
There were 48 RCTs that reported the severity of PEP.
These RCTs evaluated 15 agents in 15 671 patients. All
studies reported the severity of PEP using the consensus
criteria. Severe PEP includes hospitalisation for ≥10 days or
development of any of the following during hospitalisation:
haemorrhagic pancreatitis, pancreatic necrosis, pancreatic
pseudocyst, percutaneous drainage or surgery.66 Overall,
severe PEP was reported in 0.49% and 0.53% of patients in
the pharmacological agent and placebo groups respectively
(Appendix S2, Table S2). Too few events occurred to per-
form a NMA or identify trends in efﬁcacy based on indi-
vidual trial ORs for severe PEP.
Efﬁcacy of pharmacological agents to prevent PEP
mortality
There were 62 RCTs that reported on mortality due to
complications arising from PEP. These RCTs evaluated
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Figure 2 | Network of randomised controlled trials
(RCT) comparing different pharmacological agents for
their efﬁcacy to prevent post-ERCP pancreatitis. The
size of each node is proportional to the number of
randomised patients (sample size). The number
adjacent to the lines connecting agents indicates the
number of RCTs. NAC, N-acetylcysteine; IL, interleukin;
GTN, glyceryl trinitrate.
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13 agents in 16 264 patients. A total of nine deaths were
reported: three in patients receiving pharmacological
agents and six in patients receiving placebo (Appendix
S2, Table S2). Too few events occurred to perform a
NMA or identify trends in efﬁcacy to prevent PEP
related mortality.
Evaluation of consistency and heterogeneity
The Wald test for consistency (v2) was 18.90 with a P
value of 0.98, indicating that the primary outcome model
did not demonstrate inconsistency across designs. The
heterogeneity parameter was 0.39 (s.d. 0.12), indicating
the presence of heterogeneity. Our qualitative assessment
of heterogeneity led us to suspect that RCTs that
included only high-risk patients may be an important
component of the heterogeneity. After excluding RCTs
that had only high-risk patients, there was less heteroge-
neity 0.23 (s.d. 0.09) and the rank order of remaining
top-ranking agents did not change when compared with
the initial ranking (Appendix S2, Figure S2).
Sensitivity analyses
When the RCTs evaluating topical epinephrine were
excluded, the ranking of the remaining agents remained
mostly unchanged (Appendix S2, Figure S3). After
excluding topical epinephrine, the most efﬁcacious agent
was nafamostat with 61.8% probability of ranking among
top three agents followed by antibiotics (59.3%) and
NSAIDs (59.3%).
A separate analysis of the RCTs that included only
high-risk patients had six RCTs evaluating gabexate,41
NSAIDs,10 octreotide,67 somatostatin,41, 68 ulinastatin69
and IL-1056 (Appendix S2, Figure S4). NSAIDs ranked
as the most efﬁcacious agent to prevent PEP in these
RCTs evaluating high-risk patients (Appendix S2, Figure
S5). Topical epinephrine and nafamostat have not been
evaluated in a trial of only high-risk patients.
The model to evaluate the agents based on the route
of administration and dose did not reach equilibrium
after 1 000 000 iterations, prohibiting the report of
quantitative comparisons.36 Instead of relying on statisti-
cal results, we examined the direction and magnitude of
the individual RCT ORs. There was no clear trend in
efﬁcacy by dose or route (Appendix S2, Table S4).
After excluding RCTs that evaluated oral NSAIDs and
intramuscular NSAIDs, leaving only rectal NSAIDs, the
rank order of the agents changed. Topical epinephrine
continued to be the most efﬁcacious agent to prevent
EPINEPHRINE
NAFAMOSTAT
ANTIBIOTICS
NSAIDs
SECRETIN
SOMATOSTATIN
GABEXATE
GTN
HEPARIN
N-ACETYLCYSTEINE
NIFEDEPINE
ULINASTATIN
ALLOPURINOL
IL-10
CORTICOSTEROIDS
OCTREOTIDE
PLACEBO
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PROBABILITY OF RANKS
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3rdBEST
Figure 3 | Rankograms comparing the pharmacological agents to prevent post-ERCP pancreatitis. The vertical axis lists
the agents evaluated. The horizontal axis lists the probability of achieving the best, second best or the third best rank
based on repeated draws of the algorithm. The agent with the longest bar indicates the most efﬁcacious agent. The
total probability for top three ranks together is 300%.
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PEP, with an 85.4% probability of being ranked in the
top three positions; however, rectal NSAIDs moved from
a fourth to second rank (58.1%) followed by nafamostat
(48.4%), antibiotics (42.6%), secretin (24.5%) and
somatostatin (16.7%).
The NNT for topical epinephrine was 15, while it was
19 for rectal NSAIDs. The corresponding NNT values
for each of the other agents are listed in Table 1.
DISCUSSION
Despite the numerous agents evaluated in prior RCTs
and in clinical use for the prevention of PEP, the major-
ity of agents have not been compared in head-to-head
RCTs. We conducted a NMA of 16 pharmacological
agents evaluated in 99 RCTs involving 25 313 patients as
well as several sensitivity analyses and found that topical
epinephrine and rectal NSAIDs are the most efﬁcacious
agents for the prevention of PEP.
The top six agents, from most to least efﬁcacious for
preventing PEP, were topical epinephrine, rectal NSAIDs,
nafamostat, antibiotics, secretin and somatostatin
(Figure 4). The sharp demarcation in the probability of
ranks, between topical epinephrine and the other agents,
indicates that topical epinephrine should be further eval-
uated in future studies. Similarly, the difference between
the sixth ranking agent, somatostatin, and the seventh
ranking agent, gabexate, highlights the limited efﬁcacy of
those agents ranking from seventh to 16th and suggests
that future clinical trials should exclude these agents
from further study.
There were agents that share a similar mechanism of
action, but had widely discrepant ranks. For example,
nafamostat, gabexate and ulinastatin are all protease
inhibitors, but nafamostat ranked higher than gabexate
and ulinastatin. This is probably because of the higher
potency70 and longer duration of action71 of nafamostat.
Somatostatin and octreotide are also similar for their
anti-secretory properties, but somatostatin ranked higher,
potentially because octreotide causes constriction,72, 73
while somatostatin causes relaxation of the sphincter of
Oddi.74
There were two RCTs comparing topical epinephrine
with placebo and these were conducted at different cen-
tres in Asia.75, 76 The primary limitations of these studies
were that they included only patients undergoing diag-
nostic ERCP and both utilised an ERCP protocol that
mandates that a more experienced endoscopist complete
difﬁcult procedures. While patients undergoing diagnos-
tic ERCP are typically considered to be at low risk for
PEP,2 it should be noted that, in the epinephrine trial
conducted by Xu et al.,75 9% of the patients had acinari-
sation and the mean number of pancreatic duct contrast
injections was 4.6. This suggests that many patients
became high risk due to procedural interventions. How-
Table 1 | Odds ratios and number needed to treat of each agent compared with placebo ordered based on the results
of the rankogram
Rank Agent
Number of RCTs comparing
the agent with placebo
Number of patients
in treatment arm
OR of agent compared
with placebo (95% PI) NNT
1 Topical epinephrine 2 646 0.25 (0.06–0.65) 15
2 Rectal NSAIDs 8 1017 0.37 (0.21–0.59) 19
3 Nafamostat 3 626 0.41 (0.17–8.34) 20
4 Antibiotics 4 1082 0.46 (0.15–1.07) 21
5 Secretin 2 429 0.62 (0.18–1.61) 31
6 Somatostatin 18 1759 0.47 (0.30–0.70) 22
7 Gabexate 7 1631 0.59 (0.35–0.95) 29
8 GTN 9 1082 0.61 (0.36–0.97) 30
9 Heparin 3 313 0.91 (0.32–2.04) 135
10 N-acetylcysteine 2 179 1.1 (0.34–2.67) 123
11 Nifedipine 3 205 1.03 (0.36–2.35) 408
12 Ulinastatin 5 678 0.82 (0.40–1.49) 67
13 Allopurinol 6 986 0.76 (0.41–1.26) 50
14 IL-10 2 383 0.95 (0.41–1.89) 243
15 Steroids 6 1221 0.97 (0.55–1.59) 406
16 Octreotide 22 2179 0.79 (0.53–1.13) 57
RCT, randomised controlled trial; GTN, glyceryl trinitrate; IL, interleukin; OR, odds ratio; PI, probability intervals; NNT, number
needed to treat.
Odds ratio of less than 1 indicates the pharmacological agent to be protective.
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ever, these particular limitations and other methodologi-
cal limitations can be similarly found in all of the trials
evaluating the other top-ranking agents in the present
NMA. It should be highlighted that we conducted several
sensitivity analyses and found that the rank order of the
top six agents did not change after excluding each indi-
vidual agent from the analysis. Interestingly, when we
excluded only the epinephrine trials and re-evaluated the
rank order, nafamostat ranked in the top position fol-
lowed by antibiotics and then NSAIDs.
There are several possible explanations for why topical
epinephrine was found to be the most efﬁcacious agent for
the prevention of PEP. Although the pathophysiology of
PEP is not well understood,77–79 several human2–4, 80–82
and animal83 studies support the important role that pan-
creatic ductal outﬂow obstruction due to papillary oedema
plays in the development of PEP. Topical application of
epinephrine induces arteriolar vasoconstriction in the pap-
illary vasculature that reduces oedema and subsequent
pancreatic ductal outﬂow obstruction.84, 85 Topical epi-
nephrine has also been shown to relax duodenal muscula-
ture86 and the sphincter of Oddi,87 both of which also
reduce pancreatic outﬂow obstruction. The concept of
pancreatic ductal outﬂow obstruction as an early step in
the pathogenesis of PEP has been espoused in prior
reviews.77, 78 By reducing pancreatic ductal outﬂow
obstruction, topical epinephrine acts at an early point in
the pathogenesis of PEP. In addition, the local application
of epinephrine increases the likelihood of it acting within
this early therapeutic window and represents a clear
advantage over other agents, which act on a more down-
stream point in the pathogenesis of PEP when the inﬂam-
matory cascade may no longer be attenuated. A topical
agent also carries certain advantages over agents that are
administered through different routes. For example, rec-
tally administered agents may be expelled due to endo-
scopic air insufﬂation of the bowel or incomplete
absorption.88, 89 Rectal agents can also be difﬁcult for
endoscopy staff to administer when patients undergo
ERCP in the supine position.
Due to its ability to reduce pancreatic ductal outﬂow
obstruction, topical epinephrine essentially acts as the
‘pharmacological equivalent’ of a pancreatic stent.
Numerous RCTs have shown the superiority of pancre-
atic stents over no stent for preventing PEP in high-risk
patients.90 The key difference between topical epineph-
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rectal NSAIDs; rankograms comparing pharmacological agents to prevent post-ERCP pancreatitis. The vertical axis
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rine and pancreatic stents is the short duration of action
of epinephrine. However, one RCT reported that 60% of
prophylactic pancreatic stents spontaneously migrate
within 24 h91 with no difference noted in the incidence
of PEP between this group and those in whom the pan-
creatic stents remained in situ. Another study reported
that the mean time for spontaneous pancreatic stent dis-
lodgement can be as little as 2.1 days.92 These studies
suggest that pancreatic stents may also act within a nar-
row therapeutic window. In addition, pancreatic stents
have many drawbacks, including technical difﬁculty with
placement as well as the cost of stents and follow-up
endoscopy commonly required for stent removal.
When only RCTs evaluating rectal NSAIDs were
included in the model, rectal NSAIDs ranked second
after topical epinephrine. Rectal NSAIDs are the only
pharmacological agents currently recommended in clini-
cal guidelines9 based on their efﬁcacy, low cost, favour-
able safety proﬁle and widespread availability. While
nafamostat and antibiotics ranked in the third and
fourth positions, there are several reasons limiting their
use in clinical practice. Nafamostat is intravenously
administered over an extended time period before, dur-
ing and after ERCP. One study administered nafamostat
for as long as 24 h.55 The primary limitation of antibiot-
ics is microbial resistance, which is already a signiﬁcant
global health problem.93
A closer examination of route of administration, dose,
cost, advantages and disadvantages of each of the six
top-ranking agents from the present NMA suggests that
topical epinephrine and rectal NSAIDs are both inexpen-
sive, widely available, easy to administer and associated
with few side effects. The costs of rectal NSAIDs and
topical epinephrine, $1.12 and $0.24,94 respectively, are
much lower than the cost of prophylactic pancreatic duct
stent placement, which can range from $160 to
$508.95, 96 Given that topical epinephrine and rectal
NSAIDs act to counter different steps in the pathogene-
sis of PEP, i.e. pancreatic ductal outﬂow obstruction and
the inﬂammatory cascade, respectively, they can poten-
tially be used in combination for a synergistic effect. A
recent meta-analysis concluded that NSAIDs are only
able to reduce the incidence of PEP from 13.9% to 8%.29
It is possible that the concomitant use of topical epi-
nephrine and rectal NSAIDs could further reduce the
incidence of PEP.
There are several limitations to the present NMA. The
ﬁrst is the inclusion of RCTs that enrolled patients with
wide discrepancies of risk for developing PEP, as this
results in statistical heterogeneity. However, when we
excluded trials of only high-risk patients from our NMA,
there was less heterogeneity and the rank order of agents
did not change. A separate analysis of the trials that
included only high-risk patients showed a similar rank-
ing of agents, although topical epinephrine was not eval-
uated in high-risk patients. It is also important to
emphasise that there is currently no method to quantify
the risk of developing PEP based on known demo-
graphic, clinical and procedural risk factors. This limita-
tion essentially affects not only our NMA but also all
RCTs conducted in this ﬁeld. The second limitation is
the use of pancreatic duct stents, in addition to drugs,
for PEP prophylaxis in some of the trials. While we were
not able to control for the effect of pancreatic stenting in
our NMA, pancreatic stenting was performed in only a
small percentage of patients, equally distributed in the
intervention and placebo arms, and in more recent trials
and, therefore, did not signiﬁcantly impact the perfor-
mance of the drugs in the NMA.
It must be emphasised that the objectives of NMA dif-
fer from conventional meta-analyses. While conventional
meta-analyses summarise evidence from RCTs for a par-
ticular agent(s) and provide evidence for framing man-
agement guidelines, NMA summarises evidence from
multiple competing interventions simultaneously and
provides direction for future research and clinical prac-
tice. Our study identiﬁed potential sources of heterogene-
ity across trials and recommends exclusion of relatively
poor performing agents and further evaluation of better
performing agents.
In conclusion, the present network meta-analysis
found that topical epinephrine and rectal NSAIDs are
the best performing agents to prevent PEP. Future trials
are needed to determine whether topical epinephrine,
alone or in combination with rectal NSAIDs, can effec-
tively reduce or further reduce the incidence of PEP.
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